Curated News
By: NewsRamp Editorial Staff
July 03, 2025
Oragenics Secures $16.5M to Advance Concussion Treatment
TLDR
- Oragenics secures $16.5 million through a public offering, offering investors a chance to benefit from its innovative intranasal therapeutics for neurological disorders.
- Oragenics raised $16.5 million by selling 660,000 units of Series H Convertible Preferred Stock and Warrants at $25.00 per unit, funding clinical development and operations.
- Oragenics' funding advances the development of ONP-002 for concussion, promising a future with better treatments for neurological disorders and improved patient outcomes.
- Discover how Oragenics is pioneering intranasal therapeutics for concussions and neurological disorders, with a recent $16.5 million boost to fuel groundbreaking research.
Impact - Why it Matters
This news is crucial for investors and the medical community alike, as it highlights Oragenics' progress in developing innovative treatments for neurological disorders. The successful funding round not only accelerates the development of ONP-002 for concussion but also underscores the potential of intranasal therapeutics in addressing complex medical conditions. For patients suffering from mTBI and NPC, this represents a beacon of hope for future therapies. Additionally, the role of platforms like InvestorWire in amplifying such news ensures that breakthroughs in biotechnology reach a broad audience, fostering greater awareness and investment in cutting-edge medical research.
Summary
Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company, has successfully closed its public offering of Series H Convertible Preferred Stock and Warrants, raising approximately $16.5 million in gross proceeds. This significant financial boost will primarily fund the clinical development of ONP-002, a promising treatment for concussion, alongside repaying a $3 million bridge note and supporting ongoing research and development efforts. Dawson James Securities played a pivotal role as the sole placement agent in this venture. Oragenics is at the forefront of developing intranasal therapeutics aimed at addressing neurological disorders and infectious diseases, with a particular focus on innovative treatments for conditions like mild traumatic brain injury (mTBI) and Niemann Pick Disease Type C (NPC). For more details on this groundbreaking development, visit the full press release here.
InvestorWire, a specialized communications platform within the Dynamic Brand Portfolio @ IBN, has been instrumental in disseminating this news, leveraging its extensive network to ensure wide-reaching impact. This platform offers a comprehensive suite of services designed to enhance corporate communications, from press release syndication to social media distribution, making it a vital tool for companies looking to amplify their message. Discover more about InvestorWire's capabilities at InvestorWire.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oragenics Secures $16.5M to Advance Concussion Treatment
